galinpepimut-s + pembrolizumab

Galinpepimut-s + pembrolizumab is an experimental combination therapy under clinical investigation primarily for **Wilms Tumor 1 (WT1)-positive platinum-resistant advanced ovarian cancer**. Galinpepimut-s (GPS) is a *heteroclitic peptide vaccine immunotherapy* that targets the WT1 protein, a tumor-associated antigen highly expressed in various cancers, inducing a WT1-specific T-cell response to mount anti-tumor immunity. Pembrolizumab (Keytruda) is a *monoclonal antibody checkpoint inhibitor* that blocks the PD-1 receptor on T-cells, restoring and augmenting anti-tumor immune responses. The combined approach aims to prime and activate cellular immunity (via GPS) and enhance effector function by removing checkpoint inhibition (via pembrolizumab). This combination has demonstrated extended median overall survival and improved immune response compared to historical controls and pembrolizumab monotherapy, with a manageable safety profile in phase 1/2 clinical trials[1][2][6].